Gothenburg, June 18, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company's commercially available platform iTANK,announces that the company held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company's iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.
During the meeting, Elicera presented its proposed trial design and received supportive and constructive regulatory guidance from the MPA regarding the clinical protocol, dose-escalation strategy, and product manufacturing specifications. The agency confirmed that the submitted preclinical data package is considered sufficient to support the initiation of clinical development.
"We are very pleased with the constructive and valuable feedback from the MPA," said Jamal El-Mosleh, CEO of Elicera Therapeutics. "This guidance gives us a clear framework as we finalize the clinical trial design in parallel with process development and tech transfer of the manufacturing process. It is an important milestone on our path toward starting the first clinical study with ELC-401."